.jpeg)
2026-09-29 06:25:46
Pemigatinib is an oral FGFR1/2/3 inhibitor for advanced FGFR2 fusion/rearrangement cholangiocarcinoma and selected FGFR1-rearranged myeloid/lymphoid neoplasms. Cholangiocarcinoma uses 13.5mg once daily, 14 days on and 7 days off; FIGHT-302 and FIGHT-202 support sequencing decisions, with serum phosphate and OCT ophthalmology monitoring.
2026-09-28 04:52:25
Belumosudil is a ROCK2 inhibitor for chronic graft-versus-host disease in patients aged 12 years and older after inadequate response to prior systemic therapy. Use 200mg once daily with food; manage embryo-fetal risk and contraception, strong CYP3A inducers/PPI dosing changes, monthly liver tests, and infection or hypertension adverse events.
2026-09-28 04:44:36
Elagolix is an oral GnRH receptor antagonist that lowers LH/FSH and ovarian estrogen for moderate-to-severe endometriosis pain, including dysmenorrhea, non-menstrual pelvic pain, and dyspareunia. It is not a conventional analgesic and not an oncology targeted drug; use 150mg once daily or 200mg twice daily with bone-density, mood, liver, and pregnancy monitoring.
2026-09-28 04:39:37
Diazoxide oral suspension opens β-cell KATP channels and suppresses insulin release for hyperinsulinemic hypoglycemia. Adults/children start 3mg/kg/day up to 8mg/kg/day, infants/newborns 8–15mg/kg/day; inadequate response means re-check cause rather than simply increasing dose, with monitoring for fluid retention, hyperglycemia, hypotension, and neonatal pulmonary hypertension.
2026-09-28 04:24:07
Ambrisentan is a selective endothelin-A receptor antagonist studied as adjunctive therapy for persistent IgA-nephropathy proteinuria despite baseline treatment. Real-world data show urine protein reduction and some hematuria improvement, but hemoglobin drop, edema, hypotension, liver tests, and renal function need monitoring.
2026-09-28 04:14:55
Dabrafenib (Tafinlar) is an oral BRAF inhibitor active only in tumors with a BRAF V600E/K mutation. This guide covers its mechanism, FDA-approved indications, adult and pediatric dosing, the evidence for combining it with trametinib, and practical management of adverse reactions.
2026-09-22 08:14:01
How binimetinib adds MEK1/2 blockade to encorafenib in BRAF V600E/K unresectable or metastatic melanoma, covering mechanism, response, resistance and monitoring.
2026-09-20 04:37:17
Lemborexant is a dual orexin receptor antagonist for adults with sleep-onset or sleep-maintenance insomnia. Start 5mg at bedtime with at least 7 hours in bed, titrate to 10mg by response; assess sleep latency, night awakenings, return-to-sleep, and next-day function, and watch daytime sedation, sleep paralysis, hallucinations, and complex sleep behaviors.
2026-09-20 04:31:29
Fayuvi is an AAV9, one-time intravenous gene therapy that delivers functional SGSH for pediatric MPS IIIA with preserved neurodevelopment. Use 3.0×10¹³ vg/kg, start glucocorticoids one day before infusion, infuse over about one hour, and monitor liver enzymes, coagulation, platelets, anti-AAV9 antibodies, and long-term safety.
2026-09-20 03:21:19
Trelagliptin is a long-acting DPP-4 inhibitor for adults with type 2 diabetes, usually 100mg once weekly and 50mg weekly for moderate renal impairment. Type 2 diabetes needs ongoing management; do not stop on your own, and do not assume lifetime fixed dosing—adjust by glucose, renal function, weight, and tolerability.
2026-09-20 03:15:53
Orforglipron is Eli Lilly’s oral non-peptide GLP-1 agonist, FDA-approved in 2026 for adult obesity or overweight with weight-related conditions; ACHIEVE data show added glucose and weight control when metformin is insufficient. Metformin remains a first-line basal glucose-lowering drug. Choose by glycemic goal, body weight, GI tolerance, and approved indication.
2026-09-20 03:11:47
Fayuvi is a one-time AAV9 intravenous gene therapy that delivers functional SGSH for pediatric MPS IIIA (Sanfilippo A) with preserved neurodevelopment. It lowers CSF heparan sulfate and slows cognitive decline; monitor transaminases, blood counts, fever, TMA, amylase, and long-term integration/oncology risk.
